Endopredict (EPclin) is an RNA-based genetic score which assess the prognosis in early-stage, ER-positive, and HER2-negative breast cancer, using a panel of twelve genes (eight cancer-related genes—UBE2C, DHCR7, BIRC5, RBBP8, IL6ST, AZGP1, MGP, and STC2—and three normalization genes—CALM2, OAZ1, and RPL37A and one control gene) in conjuncture with clinical status, tumor size and node status, and it generates a score predicting distant recurrence likelihood. The gene discussed is ERBB2; the disease is neoplasm.